These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 32908071)
1. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19. Sinha S; Sehgal A; Sehgal R Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071 [TBL] [Abstract][Full Text] [Related]
2. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637 [TBL] [Abstract][Full Text] [Related]
3. Can beta-adrenergic blockers be used in the treatment of COVID-19? Vasanthakumar N Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480 [No Abstract] [Full Text] [Related]
4. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. Lores E; Wysocki J; Batlle D Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725 [TBL] [Abstract][Full Text] [Related]
5. The role of ACEIs/ARBs in COVID-19: Friend or foe? Zhou Z; Qiu Y; Tao J Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701 [No Abstract] [Full Text] [Related]
6. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371 [TBL] [Abstract][Full Text] [Related]
7. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. Zhang J; Wang M; Ding W; Wan J Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300 [TBL] [Abstract][Full Text] [Related]
8. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. Young MJ; Clyne CD; Chapman KE J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970 [TBL] [Abstract][Full Text] [Related]
9. Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Alexandre J; Cracowski JL; Richard V; Bouhanick B; Therapie; 2020; 75(4):319-325. PubMed ID: 32553503 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399 [No Abstract] [Full Text] [Related]
12. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy? Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372 [TBL] [Abstract][Full Text] [Related]
13. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. Braga CL; Silva-Aguiar RP; Battaglini D; Peruchetti DB; Robba C; Pelosi P; Rocco PRM; Caruso-Neves C; Silva PL Pharmacol Res Perspect; 2020 Aug; 8(4):e00623. PubMed ID: 32658389 [TBL] [Abstract][Full Text] [Related]
14. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Cadegiani FA; Goren A; Wambier CG Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806 [TBL] [Abstract][Full Text] [Related]
15. COVID-19: A Concern for Cardiovascular Disease Patients. Sharma S Cardiovasc Toxicol; 2020 Oct; 20(5):443-447. PubMed ID: 32729064 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682 [TBL] [Abstract][Full Text] [Related]
17. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
19. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Rossi GP; Sanga V; Barton M Elife; 2020 Apr; 9():. PubMed ID: 32250244 [TBL] [Abstract][Full Text] [Related]
20. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension? Huang Y; Xie C; Chen X; Hong Q; Huang H Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834 [No Abstract] [Full Text] [Related] [Next] [New Search]